A prospective, iterative, adaptive trial of carfilzomib‐based desensitization

Proteasome inhibitor–based strategies hold promise in transplant but have yielded varying results. Carfilzomib, a second‐generation proteasome inhibitor, may possess advantages over bortezomib, the first‐generation proteasome inhibitors. The purpose of this study was to evaluate the safety, toxicity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2020-02, Vol.20 (2), p.411-421
Hauptverfasser:	Tremblay, Simon, Driscoll, James J., Rike‐Shields, Adele, Hildeman, David A., Alloway, Rita R., Girnita, Alin L., Brailey, Paul A., Woodle, E. Steve
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged alloantibody Biomarkers - blood Bone marrow Bone Marrow - immunology Bortezomib clinical research/practice clinical trial desensitization Desensitization (Psychology) Dosage Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Graft Rejection - immunology Graft Rejection - prevention & control histocompatibility Histocompatibility antigen HLA HLA Antigens - immunology Humans Immunosuppression Therapy - methods immunosuppression/immune modulation Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Inhibitor drugs Isoantibodies - blood Kidney Transplantation kidney transplantation/nephrology Kidney transplants Male Middle Aged Neurotoxicity Oligopeptides - administration & dosage Oligopeptides - therapeutic use panel reactive antibody (PRA) Plasma cells Plasma Cells - immunology Plasmapheresis Prospective Studies Proteasome inhibitors Proteasome Inhibitors - administration & dosage Proteasome Inhibitors - therapeutic use Safety translational research/science Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!